Cancer pain and analgesia

Annals of the New York Academy of Sciences

Volumn 1138, Issue , 2008, Pages 278-298

  Christo, Paul J ^a   Mazloomdoost, Danesh ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Adjuvant therapies; Analgesia; Barriers to pain relief; Cancer; Cancer pain; Co analgesics; Malignancy; Nonopioid therapies; Opioids; Pain; Therapies; WHO 3 step analgesic ladder

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANESTHETIC AGENT; BUPRENORPHINE; CLODRONIC ACID; CODEINE; DESIPRAMINE; DEXAMETHASONE; FENTANYL; HYDROMORPHONE; IBUPROFEN; METHADONE; MORPHINE; NALBUPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; PAMIDRONIC ACID; PARACETAMOL; PENTAZOCINE; PETHIDINE; PLACEBO; PREGABALIN; TRAMADOL; UNINDEXED DRUG;

ALLODYNIA; ANALGESIA; BONE PAIN; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONFUSION; CONSTIPATION; CONVULSION; DELUSION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; ERYTHEMA; EXCITATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEALTH CARE PERSONNEL; HUMAN; HYPERPYREXIA; KIDNEY DISEASE; LIVER TOXICITY; LONG QT SYNDROME; MONOTHERAPY; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; OPIATE ADDICTION; PERCUTANEOUS VERTEBROPLASTY; PRACTICE GUIDELINE; PRURITUS; RADIOFREQUENCY ABLATION; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMATIC PAIN; TACHYCARDIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN; VOMITING; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

EID: 53149139925     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1414.033     Document Type: Conference Paper

References (150)

1. NIH. 2002. NIH State of the Science Statement on symptom management in cancer: pain, depression, and fatigue. in NIH Con. State of the Sci. Statm. 1 29.
2. Keefe, F.A., AP Abernethy & CL Campbell. 2005. Psychological approaches to understanding and treating disease related pain. Annual Rev. Psychol. 56 : 1 22.
3. Bonica, J. 1990. The Management of Pain. Vol. 1. Lea & Febiger. Philadelphia.
4. ESMO. 2007. Management of cancer pain: ESMO Clinical Recommendations. Annals of Oncology 18 (Suppl 2 ii92 ii94.
5. Jadad, A.R. & G.P. Browman. 1995. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274 : 1870 1873.
6. Azevedo, S.L.F., M. Kimura & M. Jacobsen Teizeira. 2006. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer.
7. Levy, M. 1999. Pain control in patients with cancer. Oncology (Williston Park) 13 (5 Suppl 2 9 14.
8. Polomano, R.C. & J.T. Farrar. 2006. Pain and neuropathy in cancer survivors. Am. J. Nurs. 106 (3 Suppl 39 47.
9. Portenoy, R.K. 1989. Mechanisms of clinical pain. Observations and speculations. Neurol. Clin. North Am. 7 : 205 230.
10. Loeser, J. 2001. Bonica's Management of Pain, 3rd edn. : 19 21. Lippincott, Williams & Wilkins. Philadelphia.
11. LeBel, A.A. 2002. The Massachusetts General Hospital Handbook of Pain Management, 2 edn. J.C. Ballantyne, Ed. : Lippincott Williams & Wilkins. Philadephia.
12. Foley, K. 1998. Pain assessment and cancer pain syndromes. In Oxford Textbook of Palliative Medicine. H.G. Doyle D & N. MacDonald, Eds 310 331. Oxford University Press. Oxford.
13. American Pain Society Quality of Care Committee. 1995. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA 274 : 1874 1880.
14. Baltic, T.E., M.B. Whedon, T.A. Ahles & G. Fanciullo. 2002. Improving pain relief in a rural cancer center. Cancer Pract. 10 (Suppl 1 S39 S44.
15. Lasch, K. 2002. Why study pain? A qualitative analysis of medical and nursing faculty and students' knowledge of and attitudes to cancer pain management. J. Palliat Med. 5 : 57 71.
16. Payne, R. 2000. Chronic pain: challenges in the assessment and management of cancer pain. J. Pain Symptom Manage. 19 (1 Suppl S12 S15.
17. Ward, S. 2001. Patient education in pain control. Support Care Cancer 9 : 148 155.
18. Gunnarsdottir, S. 2002. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain 99 : 385 396.
19. Ward, S. & J. Gatwood. 1994. Concerns about reporting pain and using analgesics. A comparison of persons with and without cancer. Cancer Nurs. 17 : 200 206.
20. Ward, S.E., N. Goldberg, V. Miller-McCauley, et al. 1993. Patient-related barriers to management of cancer pain. Pain 52 : 319 324.
21. Phillips, D.M. 2000. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 284 : 428 429.
22. Dahan, A. 2001. Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice. Anesthesiology 94 : 824 832.
23. Romberg, R. 2003. Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br J. Anaesth 91 : 862 870.
24. Dahan, A. 2004. Simultaneous measurement and integrated analysis of analgesia and respiration after an intravenous morphine infusion. Anesthesiology 101 : 1201 1209.
25. American Society of Addiction Medicine. 1998. Public policy statement on definitions related to the use of opioids in pain treatment. J. Addict. Dis. 17 : 129 133.
26. Portenoy, R.K. 1990. Chronic opioid therapy in nonmalignant pain. J. Pain Symptom Manage. 5 (1 Suppl S46 S62.
27. Sees, K.L. & H.W. Clark. 1993. Opioid use in the treatment of chronic pain: assessment of addiction. J. Pain Symptom Manage. 8 : 257 264.
28. McQuay, H. 1999. Opioids in pain management. Lancet 353 : 2229 2232.
29. Cancer pain relief. With a guide to opioid availability. 1996, World Health Organization.
30. Macaluso, C., D. Weinberg & K.M. Foley. 1988. Opioid abuse and misuse in a cancer pain population. J. Pain Symptom Manage. 3 : S24.
31. Passik, S.D., K.L. Kirsh, M.V. McDonald, S. Ahn, et al. 2000. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J. Pain Symptom Manage. 19 : 274 286.
32. Passik, S.D., J. Schreiber & K.L. Kirsh. 2000. A chart review of the ordering of urine toxicology screen in a cancer center: do they influence on pain management. J. Pain Symptom Manage. 19 : 44.
33. Schug, S.A., D. Zech, S. Grond, et al. 1992. A long term survey of morphine in cancer pain patients. J. Pain Symptom Manage. 7 : 259 266.
34. Foley, K.M. & N. Sundaresan. 1985. Management of cancer pain. In Cancer: Principles and Practice of Oncology. Vol. 2. V.T. DeVita, Jr., S. Hellman & S.A. Rosenberg, Eds 1940 1962. JB Lippincott Company. Philadelphia.
35. Mercadante, S. 1999. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer 85 : 1849 1858.
36. Ventafridda, V. 1987. A validation study of the WHO method for cancer pain relief. Cancer 59 : 850 856.
37. Zech, D.F. 1995. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63 : 65 76.
38. Quigley, C. 2005. The role of opioids in cancer pain. BMJ 331 : 825 829.
39. Twycross, R. & A. Wilcock 2001. Symptom Management in Advanced Cancer, 3rd edn. Radcliffe Medical Press. Oxford.
40. Miaskowski, C., J. Cleary, R. Burney, et al., Eds. 2005. Guideline for the Management of Cancer Pain in Adults and Children, Vol. Clinical Practice Guidelines Series, No. 3. American Pain Society. Glenview, IL.
41. Fourney, D.R. 2003. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J. Neurosurg. 98 (1 Suppl 21 30.
42. Neeman, Z. & B.J. Wood. 2002. Radiofrequency ablation beyond the liver. Tech. Vasc. Interv. Radiol. 5 : 156 163.
43. Krouse, R. 2004. Advances in palliative surgery for cancer patients. J. Support Oncol. 2 : 80 87.
44. McCahill, L. & B. Ferrell. 2002. Palliative surgery for cancer pain. West J. Med. 176 : 107 110.
45. Amersi, F., M.J. Stamos & C.Y. Ko. 2004. Palliative care for colorectal cancer. Surg. Oncol. Clin. North Am. 13 : 67 77.
46. Homs, M.Y. 2004. Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur. J. Cancer 40 : 1862 1871.
47. Nielsen, O.S., S.M. Bentzen & E. Sandberg. 1998. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol. 47 : 233 240.
48. Bang, S.M. 2005. Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13 : 515 521.
49. Burris, H.A. 3rd. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 : 2403 2413.
50. Ettinger, A.B. & R.K. Portenoy. 1988. The use of corticosteroids in the treatment of symptoms associated with cancer. J. Pain Symptom Manage. 3 : 99 103.
51. Watanabe, S. & E. Bruera. 1994. Corticosteroids as adjuvant analgesics. J. Pain Symptom Manage. 9 : 442 445.
52. Rousseau, P. 2001. The palliative use of high-dose corticosteroids in three terminally ill patients with pain. Am. J. Hosp. Palliat Care 18 : 343 346.
53. Jacox, A., D.B. Carr & R. Payne. 1994. New clinical-practice guidelines for the management of pain in patients with cancer. N. Engl. J. Med. 330 : 651 655.
54. McQuay, H.J. 1996. A systematic review of antidepressants in neuropathic pain. Pain 68 : 217 227.
55. Sindrup, S.H. & T.S. Jensen. 1999. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 : 389 400.
56. Mattia, C. 2002. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 68 : 105 114.
57. Backonja, M. 1998. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 : 1831 1836.
58. Bennett, M.I. & K.H. Simpson. 2004. Gabapentin in the treatment of neuropathic pain. A review. Palliat Med. 18 : 5 11.
59. Rice, A.S. & S. Maton. 2001. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94 : 215 224.
60. Dworkin, R.H. 2003. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60 : 1524 1534.
61. Freynhagen, R. 2005. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 : 254 263.
62. Wong, R & P.J. Wiffen. 2002. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). Cochrane Database Syst Rev 2 : CD002068.
63. Berenson, J.R. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334 : 488 493.
64. Bloomfield, D.J. 1998. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J. Clin. Oncol. 16 : 1218 1225.
65. Gunawardana, D.H. 2004. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin. Nucl. Med. 29 : 81 85.
66. Sartor, O. 2004. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 : 940 945.
67. Robinson, R.G., D.F. Preston, K.G. Baxter, R.W. Dusing & J.A. Spicer. 1993. Clinical experience with Strontium-89 in prostatic and breast cancer patients. Seminars in Oncology 20 : 44 48.
68. Rogers, C.L., B.L. Speiser & P.C. Ram. 1998. Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastases. J. of Brachytherapy International 14 : 133 142.
69. Sciuto, R., C.L. Maini & A. Tofani. 1996. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl. Med. Commun. 17 : 799 804.
70. Watson, A.C., S.T. Brookes, J.R. Kirwan & A. Faulkner. 2000. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2.
71. Makin, A.J., J. Wendon & R. Williams. 1995. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 109 : 1907 1916.
72. Schiodt, F.V. 1997. Acetaminophen toxicity in an urban county hospital. N. Engl. J. Med. 337 : 1112 1117.
73. Grond, S. 1991. The importance of non-opioid analgesics for cancer pain relief according to the guidelines of the World Health Organization. Int. J. Clin. Pharmacol. Res. 11 : 253 260.
74. McNicol, E. 2004. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J. Clin. Oncol. 22 : 1975 1992.
75. Mercadante, S., F. Fulfaro & A. Casuccio. 2002. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur. J. Cancer. 38 : 1358 1363.
76. Simon, L., A. Lipman, A. Jacox, M. Caudill-Slosberg, et al. 2002. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. American Pain Society. Glenview, IL.
77. Arbaiza, D. & O. Vidal. 2007. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin. Drug. Investig. 27 : 75 83.
78. Boureau, F., P. Legallicier & M. Kabir-Ahmadi. 2003. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 104 : 323 331.
79. Harati, Y. 1998. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50 : 1842 1846.
80. Shipton, E.A. 2000. Tramadol - present and future. Anaesth Intensive Care 28 : 363 374.
81. Babul, N. 2004. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J. Pain Symptom Manage. 28 : 59 71.
82. Dean, M. 2004. Opioids in renal failure and dialysis patients. J. Pain Symptom Manage. 28 : 497 504.
83. Viscusi, E.R. 2005. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology 102 : 1014 1022.
84. Eichelbaum, M. & B. Evert. 1996. Influence of pharmacogenetics on drug disposition and response. Clin. Exp. Pharmacol. Physiol. 23 : 983 985.
85. Caraco, Y., J. Sheller & A.J. Wood. 1999. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther. 290 : 413 422.
86. Gutstein, H. & A. Huda. 2006. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11 edn. Opioid Analgesics. P. Laurence & L. Brunton, Eds 566. McGraw-Hill. New York, New York.
87. Guay, D.R.P., W.M. Awni & J.W.A. Findaly. 1988. Pharmacokinetics and pharmacodynamics of codeine in end-state renal disease. Clin. Pharmacol. Ther. 43 : 63 71.
88. Matzke, G.R., G.L.C. Chan & P.A. Abraham. 1986. Codeine dosage in renal failure. Clinical Pharmacy 5 (letter 15 16.
89. Talbott, G.A. 1997. Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr (Phila) 36 : 171 173.
90. Ananthan, S. 2004. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J. Med. Chem. 47 : 1400 1412.
91. Junker, U. & V. Figge. 2005. Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study. MMW Fortschr. Med. 147 (Suppl 3 91 96.
92. Quigley, C. 2002. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews 1 (CD003447).
93. World Health Organization. 1990. Report on cancer pain relief and palliative care. World Health Organization. Geneva.
94. Hagen, N.A. & R. Swanson. 1997. Strychnine-like multifocal myoclonus and seizures from extremely high dose opioids: treatment strategies. J. Pain Symptom Manage. 14 : 51 58.
95. Smith, M. 2000. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin. Exp. Pharmacol. Physiol. 27 : 524 528.
96. Ahmedzai, S. & D. Brooks. 1997. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J. Pain Symptom Manage. 13 : 254 261.
97. Donner, B. 1998. Long-term treatment of cancer pain with transdermal fentanyl. J. Pain Symptom Manage. 15 : 168 175.
98. Radbruch, L. 2001. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med. 15 : 309 321.
99. Gutstein, H. & A. Huda. 2006. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11 edn. Opioid Analgesics. P. Laurence & L. Brunton, Eds 571. McGraw-Hill. New York, New York.
100. Muijsers, R.B. & A.J. Wagstaff. 2001. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61 : 2289 2307.
101. Hanks, G.W. 2001. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84 : 587 593.
102. Hartrick, C.T. 2006. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg. Anesth. Pain Med. 31 : 546 554.
103. Viscusi, E.R. 2004. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 291 : 1333 1341.
104. Viscusi, E.R. & T.A. Witkowski. 2005. Iontophoresis: the process behind noninvasive drug delivery. Reg. Anesth. Pain Med. 30 : 292 294.
105. Monory, K. 1999. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci. 64 : 2011 2020.
106. Yoburn, B.C. 1995. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol. Biochem. Behav. 51 : 535 539.
107. Prommer, E. 2006. Oxymorphone: a review. Support Care Cancer 14 : 109 115.
108. Bruera, E. 1998. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J. Clin. Oncol. 16 : 3222 3229.
109. Heiskanen, T. & E. Kalso. 1997. Controlled-release oxycodone and morphine in cancer related pain. Pain 73 : 37 45.
110. Mucci-LoRusso, P. 1998. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur. J. Pain. 2 : 239 249.
111. Curtis, G.B., G.H. Johnson & P. Clark. 1999. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur. J. Clin. Pharmacol. 55 : 425 429.
112. Kirvela, M. 1996. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J. Clin. Anesth. 8 : 13 18.
113. Fitzgerald, J. 1991. Narcotic analgesics in renal failure. Conn. Med. 55 : 701 704.
114. Acute Pain Management in Infants, Children, and Adolescents: Operative and Medical Procedures, in U.S. Dept. of Health and Human Services. 1992. Agency for Health Care Policy and Research. p. Rockville, MD.
115. Hershey, L. 1983. Meperidine and central neurotoxicity. Ann. Intern. Med. 98 : 548 549.
116. Cowan, A., J.W. Lewis & I.R. Macfarlane. 1977. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60 : 537 545.
117. Lee, K.O. et al. 1999. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur. J. Pharmacol. 378 : 323 330.
118. Lewis, J.W. & S.M. Husbands. 2004. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr. Pharm. Des. 10 : 717 732.
119. Gutstein, H. & A. Huda. 2006. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11 edn. Opioid Anaglesics. P. Laurence & L. Brunton, Eds 576. McGraw-Hill. New York, New York.
120. Dahan, A. 2006. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 20 (Suppl 1 s3 s8.
121. Cowan, A. 2003. Buprenorphine: new pharmacological aspects. Int. J. Clin. Pract. Suppl. 3 8 discussion 23-4.
122. Likar, R., H. Kayser & R. Sittl. 2006. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin. Ther. 28 : 943 952.
123. Pace, M.C., M.B. Passavanti, E. Grella, et al. 2007. Buprenorphine in long term control of chronic pain in cancer patients. Front Biosci. 1 : 1291 1299.
124. Sittl, R., M. Nuijten & B.P. Nautrup. 2006. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther. 28 : 1144 1154.
125. Sorge, J. & R. Sittl. 2004. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 26 : 1808 1820.
126. Christoph, T. 2005. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur. J. Pharmacol. 507 : 87 98.
127. Likar, R. & R. Sittl. 2005. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth. Analg. 100 : 781 785.
128. Griessinger, N., R. Sittl & R. Likar. 2005. Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13,179 patients. Curr. Med. Res. Opin. 21 : 1147 1156.
129. Likar, R., H. Kayser & R. Sittl. 2005. Transdermal buprenorphine for long-term management of chronic cancer and non-cancer pain. Results of an open-label, multicentre, follow up study. Book of Abstracts, International Forum on Pain Medicine. (Sofia).
130. Sittl, R. 2006. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 20 (Suppl 1 s25 s30.
131. Mystakidou, K. 2003. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J. Pain 4 : 298 306.
132. Nugent, M. 2001. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J. Pain Symptom Manage. 21 : 385 391.
133. Filitz, J. 2006. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur. J. Pain. 10 : 743 748.
134. Summerfield, R.J., M.C. Allen & R.A. Moore. 1985. Buprenorphine in end-stage renal failure. Anaesthesia 40 (Letter 914.
135. Bulka, A. 2002. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 95 : 103 109.
136. Bulka, A., Z. Wiesenfeld-Hallin & X.J. Xu. 2002. Differential antinociception by morphine and methadone in two sub-strains of Sprague-Dawley rats and its potentiation by dextromethorphan. Brain Res. 942 : 95 100.
137. Davis, M. & D. Walsh. 2001. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9 : 73 83.
138. Nicholson, A. 2004. Methadone for cancer pain. Cochrane Database of Systematic Reviews, (1): p. Art. No.: CD003971. DOI: 10.1002/14651858. CD003971. pub2.
139. Fainsinger, R., T. Schoeller & E. Bruera. 1993. Methadone in the management of cancer pain: a review. Pain 52 : 137 147.
140. Grochow, L. 1989. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain 38 : 151 157.
141. Ripamonti, C., E. Zecca & E. Bruera. 1997. An update on the clinical use of methadone for cancer pain. Pain 70 : 109 115.
142. Bryson, J. 2006. Methadone for treatment of cancer pain. Curr. Oncol. Rep. 8 : 282 288.
143. Reddy, S.F., M. Fisch & E. Bruera. 2004. Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes. J. Pain Symptom Manage. 28 : 301 303.
144. Roden, M. 2004. Drug-induced prolongation of the QT-interval. N. Engl. J. Med. 350 : 1015 1022.
145. Kreek, M.J. & C.L. Gutjahr. 1976. Drug interactions with methadone. Ann. N.Y. Acad. Sci. 281 : 350 370.
146. Kreek, M.J. & A.J. Schecter. 1980. Methadone use in patients with chronic renal disease. Drug Alcohol Dep. 5 : 197 205.
147. Hanks, G.W.C. & N. Cherny. 1998. Opioid analgesic therapy. In Oxford Text of Palliative Medicine. H.G. Doyle D & N. MacDonald, Eds 331 351. Oxford University Press. Oxford.
148. Twycross, R., A. Wilcock & S. Thorpe. 1998. Palliative Care Formulary. Radcliffe Medical Press. Oxford.
149. Sloan, P., N. Slatkin & H. Ahdieh. 2005. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 13 : 57 65.
150. Adams, M.A. & H. Ahdieh. 2005. Single and multiple dose pharmacokinetic and dose proportionality study of oxymorphone immediate release tablets. Drugs RD 6 : 91 99.